Niaid-dmid-antiviral program for pandemics early phase clinical trial(s)
Ended Awarded Last action
- Contract number
- 75N91022F00017
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,142,134
Award facts
- Contract value 100% obligated
- $6,142,134.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $6,142,134 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6.14 million cost-plus-fixed-fee delivery order to Leidos Biomedical Research Inc. on September 19, 2022, for the Antiviral Program for Pandemics Early Phase Clinical Trial(s). Work will be performed in Frederick, Maryland, with an ultimate completion date of May 31, 2026. Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc. and a Federally Funded Research and Development Center (FFRDC) contractor, will leverage its established capabilities in clinical trial support and antiviral research to advance pandemic preparedness initiatives. The contract carries no small business set-aside designation, reflecting the specialized nature of the research infrastructure and expertise required for early-phase clinical trials.
This delivery order supports NIAID's mission to develop medical countermeasures and therapeutic interventions for infectious disease threats. Leidos Biomedical Research Inc. has demonstrated extensive experience conducting clinical trials and infectious disease research through its Frederick National Laboratory operations, including prior work on COVID-19 and influenza research programs. The cost-plus-fixed-fee structure is standard for research and development work requiring flexibility in scope and resource allocation. The modification referenced in the award description regarding cancellation of unexercised options reflects government fiscal management practices to ensure efficient allocation of resources and maintain transparency in federal spending.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Allucent Government Services (Us) LLC | $3,304,126 |
Quick answers
Who was awarded contract 75N91022F00017?
75N91022F00017 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2022.
How much is contract 75N91022F00017 worth?
The government has obligated $6,142,134 on 75N91022F00017.
Which agency awarded contract 75N91022F00017?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00017, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00017 an order under another contract?
Yes. 75N91022F00017 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00017 competed?
The extent of competition for 75N91022F00017 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award